Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Ratio (2017 - 2025)

Protagonist Therapeutics' Equity Ratio history spans 9 years, with the latest figure at 0.92 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 1.45% year-over-year to 0.92; the TTM value through Dec 2025 reached 0.92, up 1.45%, while the annual FY2025 figure was 0.92, 1.45% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.92 at Protagonist Therapeutics, roughly flat from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q4 2023 and bottomed at 0.86 in Q4 2021.
  • The 5-year median for Equity Ratio is 0.89 (2021), against an average of 0.89.
  • The largest annual shift saw Equity Ratio skyrocketed 87.29% in 2021 before it decreased 4.02% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.86 in 2021, then increased by 0.78% to 0.87 in 2022, then increased by 8.16% to 0.94 in 2023, then fell by 3.59% to 0.91 in 2024, then increased by 1.45% to 0.92 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Equity Ratio are 0.92 (Q4 2025), 0.92 (Q3 2025), and 0.93 (Q2 2025).